{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.9"}]}],"title":"CIN grade 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4"}]}],"title":"FN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5"}]}],"title":"CIN/FN-related hospitalization"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8"}]}],"title":"CIN/FN-related chemotherapy disturbance"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7"}]}],"title":"Composite^"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1447"}],"units":"Participants"}],"description":"Objective 5: To describe the distribution of chemotherapy dose delays and reductions, surgery delays and cancellations, radiotherapy delays, dose reductions, and cancellations, and mortality (GCSF-related; FN-related; cancer-related; not related to GCSF, FN, or cancer; all-cause); and estimate the time-to-event for such events over the course of EP2006 treatment.\n\nTable presents incidences of outcomes on a cycle level. \\^Composite outcome includes CIN grade 4, FN, CIN/FN-related hospitalization and CIN/FN-related chemotherapy disturbance\n\nCIN: Chemotherapy-Induced Neutropenia; FN: Febrile Neutropenia; ANC: Absolute Neutrophil count; GIS: GCSF Initiation Score; Prophylaxis decision mentioned below are relative to EORTC guidelines (2010).","groups":[{"description":"Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.","id":"OG000","title":"EP2006"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"All cycles. Patients were evaluated at the enrollment cycle and then re-evaluated at each cycle for a maximum total of 6 cycles; however, the scheduling of these evaluations was left to the discretion of the physician, mean duration of study for 105 days","title":"Incidence of Outcomes: Cycles Level","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}